ArriVent BioPharma (NASDAQ:AVBP) Hits New 52-Week Low – Here’s Why

Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) reached a new 52-week low during mid-day trading on Tuesday. The company traded as low as $11.66 and last traded at $12.00, with a volume of 1687237 shares. The stock had previously closed at $28.46.

Key Stories Impacting ArriVent BioPharma

Here are the key news stories impacting ArriVent BioPharma this week:

• Positive Sentiment: Citigroup and JonesTrading retained buy ratings on ArriVent, with revised price targets of $20 and $22, respectively. Those targets remain above the stock’s recent trading level, suggesting analysts see potential recovery value if the company can successfully reposition its pipeline.
• Neutral Sentiment: ArriVent is reviewing its development plans for firmonertinib following the trial result. The company may provide additional analyses or pursue other development strategies, but the outlook and timing remain uncertain. ArriVent reviews firmonertinib plans after Phase III setback
• Negative Sentiment: ArriVent announced that the Phase 3 FURVENT trial of firmonertinib in previously untreated EGFR exon 20 insertion-mutated non-small-cell lung cancer failed to meet its primary progression-free-survival endpoint. Because firmonertinib is the company’s lead asset, the failure materially reduces the probability of a near-term commercial launch and has driven a sharp decline in the shares. ArriVent FURVENT Phase 3 program update
• Negative Sentiment: Analysts cut their price targets substantially—from $40 to $20 at Citigroup and from $45 to $22 at JonesTrading—indicating a reset in expectations even though both firms kept buy ratings.
• Negative Sentiment: Several law firms announced investigations into potential securities claims related to ArriVent’s disclosures and the company’s recent $250 million at-the-market offering. These notices do not establish wrongdoing, but they add legal and reputational risk after the trial disappointment. SueWallSt ArriVent shareholder investigation

Analyst Upgrades and Downgrades

AVBP has been the subject of a number of research reports. BTIG Research decreased their price objective on ArriVent BioPharma from $42.00 to $29.00 and set a “buy” rating for the company in a report on Wednesday. HC Wainwright raised their price target on shares of ArriVent BioPharma from $44.00 to $47.00 and gave the stock a “buy” rating in a research note on Monday, August 17th. Citigroup lowered their price objective on shares of ArriVent BioPharma from $40.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday. Cantor Fitzgerald reissued an “overweight” rating on shares of ArriVent BioPharma in a research report on Tuesday, September 22nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of ArriVent BioPharma in a report on Friday, July 17th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $29.67.

ArriVent BioPharma Price Performance

The stock has a 50-day moving average price of $29.30 and a 200-day moving average price of $29.39. The company has a market capitalization of $832.85 million, a price-to-earnings ratio of -4.67 and a beta of 1.34.

ArriVent BioPharma (NASDAQ:AVBP) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.06). Equities analysts forecast that ArriVent BioPharma, Inc. will post -4.11 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Montanova Capital LLC boosted its position in shares of ArriVent BioPharma by 2.6% in the second quarter. Montanova Capital LLC now owns 4,515,531 shares of the company’s stock valued at $156,870,000 after acquiring an additional 114,448 shares during the period. Hhlr Advisors LTD. acquired a new stake in ArriVent BioPharma in the 2nd quarter worth about $136,498,000. BlackRock Inc. bought a new stake in ArriVent BioPharma in the 2nd quarter valued at about $112,919,000. General Catalyst Group Management LLC acquired a new position in shares of ArriVent BioPharma during the 2nd quarter worth approximately $51,929,000. Finally, Vivo Capital LLC acquired a new position in shares of ArriVent BioPharma during the 1st quarter worth approximately $20,438,000. Institutional investors own 9.48% of the company’s stock.

About ArriVent BioPharma

ArriVent BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing precision medicines for patients with genetically defined cancers. The company seeks to identify promising therapies developed in other regions and advance them through clinical development and regulatory approval in the United States and other markets.

ArriVent’s lead product candidate is furmonertinib, an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor designed to target specific EGFR mutations in non-small cell lung cancer, including EGFR exon 20 insertion mutations.